Anti-VEGF monotherapy safe and effective for SRNVM

Article

Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel).

Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel), claims a paper in the journal Retina.

The retrospective chart review led by Dr Raja Narayanan, L. V. Prasad Eye Institute, Hyderabad, India, included 16 eyes of 16 patients with naïve SRNVM secondary to Mactel examined between January 2007 and April 2011. Four eyes were administered intravitreal ranibizumab monotherapy and 12 were treated with intravitreal bevacizumab monotherapy.

The primary outcome was the mean change in best-corrected visual acuity (BCVA) at the final postoperative visit. Secondary outcomes included the mean number of intravitreal injections, retinal thickness on OCT and IOP. Demographic data, medical history and ocular history were also recorded.

Mean baseline visual acuity was 0.17 ± 0.16 and the mean final visual acuity was0.27 ± 0.14. No injection-related complications were reported and the mean amount of intravitreal injections was 1.9.

To read the abstract please click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.